Look back at pharma news in the week to May 24

26 May 2019

Among noteworthy research news last week was new data for The Medicines Company’s cholesterol lowerer inclisiran showing the drug has dosing advantage. Also, Ocular Therapeutix posted disappointing results for its OTX-TP in glaucoma, but hopes to still get it approved. And Merck & Co’s blockbuster cancer drug Keytruda failed as a tripe-negative breast cancer treatment. Merck was also in the news with its proposed acquisition of biotech firm Peloton Therapeutics, which has a kidney cancer focus. Additionally, German biotech firm Evotec said it is forking out $90 million to buy US firm Just Biotherapeutics.

Long-term heart data reassures for The Medicines Co

The Medicines Company released data last Saturday from a long-term safety study of its experimental cholesterol-lowering drug inclisiran in heart disease patients, showing the therapy maintained its benefit three years post treatment while leading to fewer side effects than its would-be rivals Amgen’s Repatha and Sanofi and Regeneron’s Praluent, noted Jonathan Gardner writing on BioPharma Dive.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK